1	Impact of Cushing's syndrome on the hypothalamus-pituitary-gonad axis in
2	women
3	
4	
5	
6	Anting Yu <sup>1</sup> , Xuan Liu <sup>1</sup> , Yiyu Chen <sup>1</sup> , Shuo Li <sup>1</sup> , Ming Liu <sup>1,*</sup>
7	<sup>1</sup> Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital,
8	Tianjin, China
9	
10	
11	
12	* Correspondence:
13	Ming Liu, mingliu@tmu.edu.cn, 18320017516;
14	Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital,
15	Tianjin, China
16	154 Anshan Road, Heping District, Tianjin 300052, China
17	
18	
19	
20	
21	

# 23 Abstract

24	Background: The reproductive and sexual disorders commonly occur in patient with Cushing's
25	syndrome (CS), but only few clinical studies focused on the hypothalamus-pituitary-gonad (HPG)
26	axis status in women with CS. A comprehensive spectrum of the impairment on HPG axis in
27	women with CS of different tensity and causes is needed.
28	Method: This retrospective study analyzed the status of HPG axis in 137 women with different
29	CS causes diagnosed between 2007 and May 2024, and the correlation between reproductive
30	hormones and the tensity of hypercortisolism. Receiver operating characteristic (ROC) analysis
31	was performed in 45 women with available data of plasma steroids by tandem mass spectrometry
32	(LC-MS/MS) as well.
33	Results: Women with ectopic adrenocorticotropin (ACTH) secretion (EAS) had significantly
34	higher levels of serum cortisol, 24h urinary-free cortisol (UFC), ACTH, with marked increase in
35	testosterone and decrease in Luteinizing hormone (LH) and Follicle-stimulating hormone (FSH)
36	(P<0.001).The serum cortisol and ACTH were positively associated with testosterone, while
37	negatively associated with LH and FSH, especially in postmenopausal women. Further
38	investigation of steroid profiles found plasma androgen including testosterone, Androstenedione
39	(A2), dehydrospiandrostenedione (DHEA) and dehydrospiandrostenedione sulfate (DHEAS) had
40	high sensitivity and specificity in discriminating CD from adrenal CS. Additional analysis of
41	thyroid axis found hypercortisolism had less influence on TSH compared with LH and FSH.
42	Conclusion: Excessive cortisol caused by CS can impair the HPG axis in women, which were
43	especially intense in EAS. The degrees of impairment were associated with the intensity and the
44	underlying causes of hypercortisolism.

45 Keywords: Cushing's syndrome/HPG axis/ectopic ACTH syndrome/serum steroids/mass

- 46 spectrometry
- 47

### 48 Introduction

49	Cushing's syndrome (CS), as a chronic and systemic endocrine disease caused by long-term and
50	excessive exposure to glucocorticoids, can leads to a myriad of clinical manifestations and
51	complications. CS traditionally comprises two subgroups: ACTH-dependent CS, which account
52	for 70-80% of CS, and ACTH-independent CS (AI-CS).[1] ACTH-dependent CS is most
53	commonly caused by Cushing's disease (CD) (80-90%), and more rarely ectopic ACTH secretion
54	(EAS) (10-20%), whose discrimination from Cushing's disease is considered challenging[2,
55	3] .ACTH-independent CS is most frequently caused by unilateral adrenal adenomas (70-80%)[1].
56	The clinical complications of CS primarily include systematic arterial hypertension, impairment of
57	glucose and lipid metabolism, musculoskeletal disorders, neuropsychiatric disorders, impairment
58	of reproductive and sexual function and dermatological manifestations. Reproductive and sexual
59	disorders commonly occur in patients with CS, and most frequently represented as decreased
60	libido and hypogonadism in men and menstrual irregularity in women[4]. It is widely accepted
61	that the hypothalamus-pituitary-gonad (HPG) axis can be affected by hypercortisolism at different
62	levels, which accounts for the reproductive and sex disorders[5, 6]. Besides, excessive cortisol
63	secretion can also impair the function of hypothalamus-pituitary-thyroid (HPT) axis[7].
64	Recently, some clinical studies has investigated the impact of CS on HPG axis in men, pointed out

- 65 that hypercortisolism can lead to reversible hypogonadotropic hypogonadism in men[8, 9].
- 66 Though the female predominance exist in CS of different causes[1], only a few studies focused on

- 67 the HPG status in women with CS in clinic[10-12], and rarely investigated the impairment of
- 68 different subtypes of CS on HPG axis and its correlation with the tensity of hypercortisolism. Thus
- 69 the aim of this retrospective study was to investigate the clinical status of HPG axis in women
- 70 affected by different causes of CS and varying intensity of hypercortisolism.
- 71

### 72 Materials and methods

- 73 Setting
- 74 This was a retrospective study at the department of Endocrinology and Metabolism at Tianjin
- 75 Medical University General Hospital. All coded medical records of women patient with CS
- 76 assessed in routine care between 2007 and May 2024 were analyzed.

### 77 Clinical evaluation

78 All patient were hospitalized at Tianjin Medical University General Hospital to undergo a full 79 diagnostic work-up. The diagnosis of Cushing syndrome was based on clinical features and at 80 least 2 of the following: (1) 24-h urinary free cortisol excretion (>300 nmol/24 h) in at least 2 81 samples; (2) 1-mg overnight dexamethasone suppression test (0800 h plasma cortisol>50 nmol/L) 82 [13]; (3) 48 h, 2 mg/d dexamethasone suppression test urinary free cortisol>27 nmol/24 h [14]. 83 Majority of the diagnoses of adrenal Cushing's syndrome was histologically confirmed. The 84 diagnosis of Cushing disease was established if pathological examination of the pituitary surgical 85 specimen confirmed the diagnosis, or if the condition resolved after resection or irradiation of the 86 pituitary gland. The diagnosis of an ectopic cause of ACTH secretion was confirmed by 87 histological examination of surgical or biopsy specimen. Nonetheless, not all sources of ACTH 88 excess were confirmed, in this case, presumed diagnosis was extracted from diagnostic code at

89 discharge. The diagnoses were made at the discretion of the attending physician, based on clinical

90 presentation, results of high-dose dexamethasone test, pituitary MRI, chest and abdominal CT.

#### 91 Hormone assays

- 92 Preoperative blood samples were obtained in the morning between 06:00 to 08:00 from an 8h 93 fasting blood draw to minimize potential confounding introduced by circadian rhythmicity and 94 food intake. Plasma ACTH, cortisol and 24-h excretion of urinary free cortisol were measured 95 using chemiluminescent enzyme immunoassay (Siemens Healthcare Diagnostics Inc., Erlangen, 96 Germany). The reproductive hormones (FSH, LH, estradiol, testosterone) were measured at the 97 early time of primary diagnosis, and determined by chemiluminescence as well. 98 Only 45 women with CS were available to measure the plasma steroids by MS, and the steroid 99 profile includes the following: progesterone, 17-hydroxyprogesterone, DHEA, DHEAS, 100 androstenedione, testosterone, 11-deoxycorticosterone, 11-deoxycortisol, corticosterone 101 and cortisone. After appropriate sample preparation, the blood was centrifuged at 14,000g for 10 102 minutes. A 100  $\mu$ L aliquot of the supernatant was then analyzed using a Jasper<sup>TM</sup>
- high-performance liquid chromatography system coupled with an ABSCIEX Triple Quad<sup>TM</sup> 4500
- 104 MD mass spectrometer, equipped with a heated nebulizer ionization source operating in positive
- 105 ion mode. Quantification of the data was performed using MultiQuant<sup>TM</sup> MD 3.0.3 software.
- 106 Statistic analysis

Statistical analysis was performed using GraphPad Prism version 9.0, IBM SPSS Statistics version
25 and R (a language and environment for statistical computing). Standard descriptive analyses
were used to summarize the study variables. Shapiro's test was applied to test for normality. For
quantitative variables, comparisons between controls and cases at baseline were performed by

111	unpaired Student's t-tests (or Mann-Whitney tests if the distribution of the variable was not
112	log-normal). Comparison between the three subgroups of CS was conducted by ordinary one-way
113	ANOVA in case of homoscedasticity or Kruskal-Wallis instead. The simple linear regression was
114	used to study the association between Cushing's indexes and reproductive outcomes at baseline.
115	The receiver operating characteristic (ROC) curve analysis was performed to test the usefulness of
116	plasma androgens as markers for differentiating between adrenal CS and CD.The optimal cutoff
117	values were determined using the Youden index (sensitivity + specificity -1). A p-value $<0.05$ was
118	considered statistically significant.
119	
120	Results
121	Demographic and clinicopathological characteristics
122	287 female patients clinically suspected as Cushing's syndrome were considered for inclusion in
123	this study to begin with. After the exclusion of subclinical CS, iatrogenic CS and patients lacking
124	sexual hormone assays, only 137 women with CS served as study's population, including 63 with
125	adrenal CS, 57 with CD and 17 with EAS. Of note, the source of ectopic ACTH secretion include
126	5 thymic neuroendocrine tumor, 3 gastrointestinal carcinomas, 2 pheochromocytomas, 1 renal
127	clear cell carcinoma, 1 lung neuroendocrine tumor, 1 small cell lung carcinoma and 1 pancreatic
128	neuroendocrine tumor.
129	Gonadotrope axis in women patient with Cushing's syndrome
130	The basic information and hormonal characteristics of study's cohort are shown in Table 1. No
131	significant difference in body mass index (BMI) were showed. But the mean age of EAS was
132	older than the other two subgroups, comport with previous report [3]. The three subgroups of

133	women with CS have markedly different levels of ACTH (AI-CS <cd<eas), th="" the<="" whereas=""></cd<eas),>
134	intensity of hypercortisolism, represented by serum cortisol and 24h-UFC, only significantly
135	higher in women with EAS (P<0.001).
136	Comparisons of reproductive hormones between women with different CS are detailed in Figure 1.
137	There was no much difference in serum estradiol level between adrenal CS, CD and EAS.
138	Conversely, the testosterone levels significantly increased in women with EAS and CD in
139	comparison with AI-CS (P<0.001), and rather higher in EAS (P<0.001) (Figure 1 A, B). Both
140	circulating LH and FSH levels in women with EAS markedly decreased, showing significant
141	differences with the other two subgroups. But the LH and FSH levels of women with CD did not
142	significantly differ from AI-CS (Figure 1 C, D). Furthermore, the FSH:LH ratios were also
143	calculated and compared, and the EAS showed markedly higher FSH:LH ratio than AI-CS
144	(P<0.001) and CD (P=0.002), while no marked difference existed between AI-CS and CD
145	(supplementary figure S1).

# 146 Linear regression between hypercortisolism intensity and reproductive hormones in

147 premenopausal and postmenopausal women

It is a general consensus that the level of women's reproductive hormones have clear periodicity and regulate the menstruation [15], thus the study's group was further divided into the premenopausal women and the postmenopausal women, detailed in Table 2. As shown, most women with EAS were postmenopausal (premenopause, n=5; psomenopause, n=12), with significantly higher levels of serum cortisol, 24h-UFC, ACTH and testosterone levels, and lower levels of LH and FSH. It is noteworthy that the LH and FSH levels reached a more significant difference in postmenopausal women with EAS in comparison with adrenal CS and CD

(Supplementary Figure S2). The serum cortisol and 24h UFC levels did no significantly differ between AI-CS and CD neither in premenopause nor postmenopause women, while the ACTH and testosterone levels were higher in CD than AI-CS in both situations, similar with above (Table 1). The estradiol levels still showed no difference among the three subgroups neither in premenopausal women nor in postmenopausal women.

For the sake of investigating the relationship between the tensity of hypercortisolism and the HPG 160 161 axis impairment, linear regression analyses between serum cortisol and the reproductive hormones 162 were performed, detailed in Figure 2. As shown, in postmenopausal women, serum cortisol was 163 significantly and negatively associated with FSH (P=0.014) and LH (P=0.016), while positively 164 associated with testosterone (P<0.001). Similar analyses were performed in premenopausal 165 women with CS as well, and found that serum cortisol did not significantly associated with LH or 166 FSH. Only testosterone was positively associated with serum cortisol in premenopausal women 167 with CS (P<0.001). Of note, the linear regression curves in postmenopausal women described 168 those relationships better, which are demonstrated by Pearson's correlations[16].

The linear regression between ACTH, 24h-UFC and reproductive hormones are presented in Supplementary Table S1. The results were quiet similar with serum cortisol when studying the relationship between ACTH and reproductive hormones, showing significant correlations with testosterone in both situations, but only in postmenopausal women ACTH did significantly correlate with LH and FSH. Moreover, the 24h-UFC only showed significant correlation with testosterone, and merely did correlate with LH or FSH in neither situations. Still, serum estradiol did not correlate with any parameters of CS in any situations.

#### 176 The characteristics of steroid profiles in adrenal CS and Cushing's disease

177	The measurement of plasma steroids by MS was only available in 45 women with CS, detailed in
178	Table 3 (AI-CS, n=24; CD, n=21). As shown, plasma androgen including testosterone, A2, DHEA
179	and DHEAS significantly increased in women with CD compared with AI-CD (P<0.001)
180	(Supplementary Figure S3). Additional linear regression analyses between ACTH and DHEA and
181	DHEAS were performed as well, and showed significant and positive association between them
182	(supplementary figure S4), comport with the general acceptance that DHEA and DHEAS are
183	majorly determined by ACTH levels [17]. Except plasma androgen, only 11-Deoxycortisol
184	(P=0.011) and 11-deoxycortisterone (P=0.006) moderately decreased in women with CD.
185	The receiver operating characteristic curve (ROC) analyses were applied to assess the diagnostic
186	power of plasma androgen in differentiating CD from adrenal Cushing's syndrome, and detailed in
187	Table 4 and Figure 3. As shown, the testosterone had a sensitivity of 81.0% and a specificity of
188	83.3%, with a cutoff value of 172.5 pg/ml and an AUC of 0.816. The androstenedione had a
189	sensitivity of 100.0% and a specificity of 83.3%, with a cutoff value of 917.5 pg/ml and an AUC
190	of 0.829. The DHEA had a sensitivity of 100.0% and a specificity of 87.5%, with a cutoff value of
191	1170.5 pg/ml and an AUC of 0.972. The DHEA-S had a sensitivity of 100.0% and a specificity of
192	83.3%, with a cutoff value of $0.27*10^{6}$ pg/ml and an AUC of 0.958. Taken together, all four
193	plasma androgen can effectively discriminate between adrenal CS and CD, with high sensitivity
194	and specificity at the best cutoff, especially DHEA and DHEAS.
195	Thyroid axis in women patient with Cushing's syndrome
196	Due to the Interest in the impact of hypercortisolism on HPT axis, and the high prevalence of

197 thyroid function test, the data of thyroid hormone was also collected, detailed in Table1 and Figure

198 4. As shown, only serum FT3 levels in women with EAS markedly decreased compared to adrenal

199	CS and CD (P<0.01), either FT4 nor TSH showed much difference (figure 5A, B). The FT3:FT4
200	ratios were further calculated and compared, and reflected a more distinguishing difference in
201	EAS compared with AI-CS and CD as well(P<0.001) (Figure 5C), which statistically indicated the
202	prominent effect of cortisol-meditated inhibition on peripheral deiodination [7]. The linear
203	regression analyses between hypercortisolism and thyroid hormones were also performed, detailed
204	in supplementary figure S5. Only the FT3 showed a moderate correlation with serum cortisol,
205	24h-UFC and ACTH, neither FT4 nor TSH did significantly correlate with any parameters of CS.
206	
207	Discussion
208	This study successfully characterizes the impact of hyercortisolism on gonadotrope axis in women
209	with CS of different causes, and further clarifies its correlation with the intensity of
210	hypercortisolism. The steroids profiles between CD and adrenal CS in a limited group is
211	investigated as well, offering a more profound insight into the changes of sexual hormones. The
212	effects of CS on HPT axis is also mentioned, in comparison with the HPG axis.
213	The primary finding of this study is the distinguishing decrease of LH and FSH, and the marked
214	
	increase of testosterone levels in women with EAS compared with adrenal CS and CD. It is wildly

confirmed in this study, and that glucocorticoids can dose-dependently impair the hypothalamus, pituitary and the reproductive tract in women[1, 5, 6], thus the decrease of LH and FSH is theoretically expected. However, there was no significant difference in estradiol between the three CS subgroups, nor correlation with the tensity of hypercortisolism in neither premenopausal cohort or in the postmenopausal cohort. This may be explained by the dual roles of

221	glucocorticoids in the ovary. The glucocorticoids have been found have both stimulatory and
222	inhibitory effects on ovary, depending on the cortisol dosage, follicular phase or GR isoforms
223	expression, and the function still remains unclear [18]. Moreover, women with EAS had markedly
224	higher FSH:LH ratio, and there has study pointed out that a basal cycle high FSH:LH ratio has a
225	negative impact on follicular development and oocyte quality [19], indicating another possible
226	mechanism by which the gonad was impaired in women with EAS.
227	This study also found significant linear associations between serum cortisol and ACTH versus
228	reproductive hormones, especially in postmenopausal women with CS, which were negative in LH
229	and FSH, while positive in testosterone. Through further dividing the study's group by the
230	menopause, we hope to exclude the influence of menstruation on reproductive hormones. And the
231	result exhibited more fitting models of linear regression for the association between the tensity of
232	hypercortisolism and LH and FSH in postmenopausal cohort, demonstrated by higher Pearson's
233	correlations [16]. Comport with previous studies [5, 6, 18], those results once again confirmed that
234	the function of HPG axis in women can be impaired by hypercortisolism, and is associated with its
235	intensity. Nevertheless, similar with previous study in men, these associations were quite
236	moderate[8], indicating that other influential factors, like personal heterogeneity and underlying
237	cause, also have influence on the degrees of gonadal impairment by hypercortisolism.
238	As mentioned above, the response of testosterone to hypercortisolism was antithetical to LH and
239	FSH, showing that more severe hypercortisolism is associated with higher plasma testosterone in
240	women with CS. Further, the steroids profile by MS showed that testosterone, A2, DHEA and
241	DHEAS were all increased in women with CD compared with AI-CS. Interestingly, this finding is
242	right inverse to the finding in men, which showed that testosterone levels were frequently lower in

243	men with CS and negatively associated with the tensity of hypercortisolism [8, 9, 20]. This
244	phenomenon suggests that the sexual dimorphism exists in testosterone's response to CS. The
245	explanation lies in that the testosterone is mainly secreted by testicle in men, and its secretion can
246	be inhibited by hypercortisolism [20], whereas in women, the testosterone is produced from
247	adrenal (25%), ovary (25%), and circulating A2 (50%), and the A2 is secreted by adrenal (50%)
248	and ovary (50%) as well [21]. As generally accepted, the adrenal androgen production is
249	stimulated by ACTH [22], which is also confirmed by this study's result, presenting significant
250	and positive correlation between ACTH and plasma androgen. Thus in women with CS, the
251	regulation of ACTH on adrenal androgen seemed have a more predominant role than the inhibition
252	of hypercortisolism on gonad.
253	The steroid profiles of CS based on MS is a hot topic recently, many studies have reported that the
254	steroid profiles can help diagnose different subtypes of CS, including clinical and subclinical CS,
255	adrenal CS, CD, EAS and so on [23-26]. The diagnostic power of plasma androgen in
256	discriminating CD and adrenal CS was also analyzed in this study, and found all the four androgen
257	can effectively differentiate CD from adrenal CS. Among them, DHEA and DHEAS can best
258	serve as diagnostic parameters with higher sensitivity and specificity, making them useful
259	supplementary measurement to confirm the causes of CS.
260	This study also investigated the impact of CS on HPT axis, but only found the peripheral
261	inhibitory effect of hypercortisolism, demonstrated by the decreased FT3 and T3:T4 ratio in EAS,
262	and the negative correlation between FT3 and hypercortisolism. The FT4 and TSH showed no

- 263 significant difference or correlation with hypercortisolism, which seemed contrary to previous
- study [7, 27]. But this result may imply that the HPG axis was more vulnerable to excessive serum

265 cortisol than the thyroid axis, since the HPG axis seemed more severely impaired than thyroid axis 266 but similar tensity of hypercortisolism. As normal thyroid function is important to maintaining 267 normal reproduction, and thyrotoxicosis and hypothyroidism can cause reproductive and sex 268 disorders in both men and women [28], extra attentions should be paid on HPG axis in those 269 patient with CS and hypothyroidism. 270 The major limitation of this study is its retrospective design, which inevitably leading to selection 271 bias, personal heterogeneity and measurement incompleteness. Besides, the 24h-UFC merely had 272 significant correlations with reproductive hormones in this study, which may attributed to the 273 retrospective design and the high degree of variability in UFC levels [29]. The limited number 274 available to MS is also a limitation, due to the low prevalence of MS, but taken previous studies 275 together [23, 24, 30], the conclusion about the steroid profiles is quiet convincing. 276 The major strength of this study is that it met the need to characterize the clinical spectrum of CS 277 on HPG axis in women with the large population. Though it is wildly received that high dose of 278 glucocorticoid can impair reproductive system [5, 6, 18], only a handful studies reported its 279 clinical status[10-12]. This study further divided the whole cohort by etiology and menopause, and 280 through investigating the differences and associations among different groups, offered more 281 comprehensive insight into the influence of hypercortisolism on HPG axis. The involvement of 282 steroid profile using MS is also the novelty of this study, provided support for plasma androgen in 283 discriminating CD from adrenal CS. Moreover, with the wild use of glucocorticoids, the result of 284 this study highlights the importance to concern the HPG axis status in women with exogenous CS

as well, especially in those who seek fertility.

286 In conclusion, the impairment of Cushing's syndrome on hypothalamic-pituitary-gonadal axis in

287	women is associated with the underlying causes and the intensity of hypercortisolism. Women
288	with ectopic ACTH syndrome incline to show a more severe impairment of HPG axis but higher
289	testosterone levels.
290	
291	Acknowledgments
292	We thank all participants from the Department of Endocrinology and Metabolism at Tianjin
293	Medical University General Hospital.
294	
295	Funding
296	This work was supported by the National Key R&D Program of China (grant numbers
297	2019YFA0802502 and 2022YFE0131400); we acknowledge the support of the National Natural
298	Science Foundation of China (grant numbers 81830025 and 82220108014), Tianjin Key Medical
299	Discipline (Specialty) Construction Project (grant number TJYXZDXK-030A), and Major Project
300	of Tianjin Municipal Science and Technology Bureau (grant number 21ZXJBSY00060).
301	
302	Ethics approval
303	The studies involving human participants were reviewed and approved by Institutional Review
304	Board of Tianjin Medical University General Hospital. The ethics committee waived the
305	requirement for written informed consent for participation.
306	
307	Human participant declaration
308	Due to the extraction of all patient data from the hospital's electronic medical records and the

anonymization of participants' identities, the study waived the requirement for informed consent.

310

### 311 statement of authorship

- 312 Anting Yu participated in data collection and drafting and editing of the paper.
- 313 Ruixuan Liu, Yiyu Chen and Shuo Li participated in data analysis.
- 314 Ming Liu participated in revision of the paper.
- 315 All authors saw and approved the final version and no other person made a substantial
- 316 contribution to the paper.

317

### 318 References

- 319 1. Gadelha, M., et al., *Cushing's syndrome*. Lancet, 2023. **402**(10418): p. 2237-2252.
- 320 2. Giuffrida, G., et al., Global Cushing's disease epidemiology: a systematic review and
- 321 *meta-analysis of observational studies.* J Endocrinol Invest, 2022. **45**(6): p. 1235-1246.
- 322 3. Hayes, A.R. and A.B. Grossman, Distinguishing Cushing's disease from the ectopic ACTH
- 323 *syndrome: Needles in a haystack or hiding in plain sight?* J Neuroendocrinol, 2022. **34**(8): p.
- **324** e13137.
- 325 4. Pivonello, R., et al., *Complications of Cushing's syndrome: state of the art.* Lancet Diabetes
- **326** Endocrinol, 2016. **4**(7): p. 611-29.
- 327 5. Whirledge, S. and J.A. Cidlowski, *Glucocorticoids and Reproduction: Traffic Control on the*
- 328 *Road to Reproduction*. Trends Endocrinol Metab, 2017. **28**(6): p. 399-415.
- 329 6. Joseph, D.N. and S. Whirledge, Stress and the HPA Axis: Balancing Homeostasis and Fertility.
- 330 Int J Mol Sci, 2017. **18**(10).

- 331 7. Paragliola, R.M., et al., *Cushing's Syndrome Effects on the Thyroid*. Int J Mol Sci, 2021. 22(6).
- 332 8. Papadakis, G.E., et al., Impact of Cushing's syndrome on the gonadotrope axis and testicular
- 333 *functions in men.* Hum Reprod, 2023. **38**(12): p. 2350-2361.
- 334 9. Zheng, H., et al., The hypothalamic-pituitary-gonad axis in male Cushing's disease before and
- 335 *after curative surgery*. Endocrine, 2022. **77**(2): p. 357-362.
- 336 10. Kaltsas, G.A., et al., How common are polycystic ovaries and the polycystic ovarian syndrome
- 337 *in women with Cushing's syndrome?* Clin Endocrinol (Oxf), 2000. **53**(4): p. 493-500.
- 338 11. Akirov, A., et al., Cushing's syndrome in women: age-related differences in etiology and
- 339 *clinical picture*. Pituitary, 2023. **26**(1): p. 144-151.
- 340 12. Keskin, F.E., et al., Sexual function in women with Cushing's Syndrome: A controlled study.
- 341 Turk J Urol, 2018. 44(4): p. 287-293.
- 342 13. Nieman, L.K., et al., The diagnosis of Cushing's syndrome: an Endocrine Society Clinical
- 343 Practice Guideline. J Clin Endocrinol Metab, 2008. 93(5): p. 1526-40.
- 344 14. Görges, R., et al., Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol
- 345 *vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group.*
- 346 J Endocrinol Invest, 1999. 22(4): p. 241-9.
- 347 15. Jabbour, H.N., et al., *Endocrine regulation of menstruation*. Endocr Rev, 2006. 27(1): p.
- 348 17-46.
- 349 16. Schneider, A., G. Hommel, and M. Blettner, *Linear regression analysis: part 14 of a series on*
- 350 *evaluation of scientific publications*. Dtsch Arztebl Int, 2010. **107**(44): p. 776-82.

- 351 17. El Asmar, N., et al., The Value of Perioperative Levels of ACTH, DHEA, and DHEA-S and
- 352 *Tumor Size in Predicting Recurrence of Cushing Disease*. J Clin Endocrinol Metab, 2018.
- **103**(2): p. 477-485.
- 18. Bhaumik, S., et al., *Glucocorticoids and Their Receptor Isoforms: Roles in Female*
- 355 *Reproduction, Pregnancy, and Foetal Development.* Biology (Basel), 2023. **12**(8).
- 356 19. Barroso, G., et al., High FSH:LH ratio and low LH levels in basal cycle day 3: impact on
- 357 *follicular development and IVF outcome*. J Assist Reprod Genet, 2001. **18**(9): p. 499-505.
- 358 20. Ren, L., et al., Dysfunction in Sertoli cells participates in glucocorticoid-induced impairment
- 359 *of spermatogenesis*. Mol Reprod Dev, 2021. **88**(6): p. 405-415.
- 360 21. Burger, H.G., Androgen production in women. Fertil Steril, 2002. 77 Suppl 4: p. S3-5.
- 361 22. Turcu, A., et al., Adrenal androgens and androgen precursors-definition, synthesis, regulation

362 *and physiologic actions.* Compr Physiol, 2014. **4**(4): p. 1369-81.

- 363 23. Hines, J.M., et al., High-Resolution, Accurate-Mass (HRAM) Mass Spectrometry Urine
- 364 Steroid Profiling in the Diagnosis of Adrenal Disorders. Clin Chem, 2017. 63(12): p.
- **365** 1824-1835.
- **366** 24. Braun, L.T., et al., *Delineating endogenous Cushing's syndrome by GC-MS urinary steroid*
- 367 *metabotyping.* EBioMedicine, 2024. **99**: p. 104907.
- 368 25. Masjkur, J., et al., Plasma Steroid Profiles in Subclinical Compared With Overt Adrenal
- 369 *Cushing Syndrome*. J Clin Endocrinol Metab, 2019. **104**(10): p. 4331-4340.
- 370 26. Eisenhofer, G., et al., *Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping*
- 371 Patients with Cushing Syndrome. Clin Chem, 2018. 64(3): p. 586-596.

- 372 27. Shekhar, S., et al., The Hypothalamic-Pituitary-Thyroid Axis in Cushing Syndrome Before and
- 373 *After Curative Surgery*. J Clin Endocrinol Metab, 2021. **106**(3): p. e1316-e1331.
- 28. Krassas, G.E., K. Poppe, and D. Glinoer, *Thyroid function and human reproductive health*.
- 375 Endocr Rev, 2010. **31**(5): p. 702-55.
- 376 29. Petersenn, S., et al., *High variability in baseline urinary free cortisol values in patients with*
- 377 *Cushing's disease*. Clin Endocrinol (Oxf), 2014. **80**(2): p. 261-9.
- 378 30. Ahn, C.H., et al., Metabolic changes in serum steroids for diagnosing and subtyping Cushing's
- 379 *syndrome*. J Steroid Biochem Mol Biol, 2021. **210**: p. 105856.
- 380

#### **Table1.** Characteristics of 137 women with Cushing's syndrome.

	Adrenal Cushing's	Cushing's	ectopic ACTH	P-value
	syndrome	disease	syndrome	
	( <b>n=63</b> )	( <b>n=57</b> )	( <b>n=17</b> )	
Age	40.11±12.60	39.95±11.09	55.65±16.15	<0.001
(years)				
Body mass index	26.15±4.19	$26.92 \pm 4.83$	27.09±5.31	0.587
(BMI)(kg/m2)				
ACTH	5.00(5.00,6.79)	66.40(46.55,114.00	225.00(123.00,481.	<0.001
(pg/ml)		)	00)	
Serum cortisol	$30.85 \pm 8.75$	33.07±11.53	$51.04{\pm}17.01$	<0.001
(ng/ml)				
Urinary-free cortisol	450.00(193.50,650.	412.20(174.65,592.	1424.50(945.00,208	<0.001
(mg/24 h)	00)	80)	1.00)	
FSH	4.54(3.00,7.48)	5.18(3.58,8.25)	1.70(0.79,3.32)	<0.001
(IU/L)				
LH	3.29(1.32,6.21)	2.58(1.06,6.92)	0.16(0.07,0.39)	<0.001
(IU/L)				
E2	34.00(15.00,91.00)	32.86(14.71,54.00)	22.80(14.50,31.67)	0.365
(pg/ml)				
Т	24.15(17.79,40.23)	52.00(38.77,72.78)	105 50/65 26	<0.001
(ng/dl)			105.50(65.20,	
			199.80)	
FSH:LH ratio	2.01(1.20,3.87)	2.62(1.64,4.64)	10.83(3.41,20.78)	<0.001
FT3	3.21±0.66	3.29±0.81	2.64±0.72	0.005
(pmol/L)				

FT3:FT4 ratio	0.29(0.25,0.31)	0.28(0.25,0.32)	0.23(0.18,0.27)	<0.001
(uIU/mL)				
TSH	0.69(0.53,1.22)	0.62(0.36,1.14)	0.49(0.23,0.91)	0.097
(pmol/L)				
FT4	11.274±1.778	$11.556 \pm 2.470$	11.86±3.54	0.613

Statistically significant results(P<0.05) were highlighted in bold.Comparison between groups was</li>
performed using one-way ANOVA or Kruskal-Wallis test if the distribution of the respective
variable was not log-normal in any of the groups. ACTH, adrenocorticotrophic hormone; FSH,
Follicle-stimulating hormone; LH, Luteinizing hormone; E2, estradiol; T, testosterone; TSH,
thyroid-stimulating hormone.

387

#### 388 Table2. Characteristics of women with Cushing's syndrome separated by menstruation.

Premenopause				
( <b>n=99</b> )				
	Adrenal Cushing's	Cushing's	ectopic ACTH	P-value
	syndrome	Disease	syndrome	
	( <b>n=50</b> )	( <b>n=44</b> )	(n=5)	
Age (years)	34.98±7.99	35.27±7.53	34.20±9.91	0.953
Body mass index	26.05±4.31	27.88±4.60	30.23±8.59	0.149
(BMI)(kg/m2)				
Serum cortisol	31.22±8.76	32.62±11.46	$52.75 \pm 3.78$	<0.001
(random)(ng/ml)				
ACTH	5.00(5.00,5.75)	65.55(46.28,108.95)	741.00(123.00,10	<0.001
(pg/ml)			83.00)	
Urinary-free	490.00(259.75,701.35)	420.70(190.40,584.10	2000.00(1225.00,	0.001
cortisol(mg/24 h)		)	2306.00)	
FSH(IU/L)	4.08(3.07,6.43)	4.84(3.90,6.14)	2.300(1.10,10.37)	0.392
LH(IU/L)	2.59(1.29,5.04)	2.57(1.13,5.51)	0.40(0.35,1.00)	0.009
E2(pg/ml)	47.00(21.54,97.65)	36.00(22.50,62.06)	28.72(26.29,135.5	0.620
			0)	
T(ng/dl)	24.42(16.71,41.21)	52.48(41.48,71.40)	244.20(139.95 ,	<0.001

Postmenopause (n=38)				
	Adrenal Cushing's syndrome	Cushing's Disease	ectopic ACTH syndrome	P-value
	( <b>n=13</b> )	( <b>n=13</b> )	( <b>n=12</b> )	
Age (years)	59.85±5.24	55.77±4.34	64.58±6.88	0.001
Body mass index	26.55±3.85	23.67±4.24	26.79±4.51	0.127
(kg/m2)				
Serum cortisol	29.41±8.94	33.49±11.68	50.33±20.34	0.002
(random)(ng/ml)				
ACTH	5.00(5.00,9.32)	66.40(40.25,128.00)	220.50(83.45,328.	<0.001

457.46)

(pg/ml)			00)	
Urinary-free	299.00(147.75,503.10)	233.80(130.53,721.70	1212.50(785.00,2	0.001
cortisol		)	012.50)	
(mg/24 h)				
FSH(IU/L)	42.04(1.38,68.35)	23.33(2.14,45.13)	1.230(0.78,2.44)	0.012
LH(IU/L)	16.93(1.82,18.79)	9.03(0.18,19.56)	0.150(0.07,0.25)	0.021
E2(pg/ml)	11.00(10.00,16.50)	12.690(10.00,28.50)	16.00(13.10,28.46	0.267
			)	
T(ng/dl)	24.15(20.64,39.13)	47.70(33.17,73.56)	85.26(55.85,114.4	0.008
			4)	

Statistically significant results(P<0.05) were highlighted in bold.Comparison between groups was</li>
 performed using one-way ANOVA or Kruskal-Wallis test if the distribution of the respective
 variable was not log-normal in any of the groups.ACTH: adrenocorticotrophic hormone; FSH:

**392** Follicle-stimulating hormone; LH: Luteinizing hormone; E2: estradiol; T: testosterone.

393

## 394 Table3.Characteristics of steroid profile in 45 women with CS

	Adrenal Cushing's	Cushing's disease	P-value
	syndrome	( <b>n=21</b> )	
	( <b>n=24</b> )		
Age	42.75±11.80	39.00±9.84	0.257
(years)			
Body mass index	27.47±4.35	26.81±4.84	0.633
(kg/m2)			
Progesterone	116.00(115.00,217.50)	120.00(100.00,299.50)	0.936
(pg/ml)			
17-hydroxyprogesterone	287.00(240.50,638.75)	532.00(209.00,815.00)	0.481
(pg/ml)			
Testosterone	107.50(96.00,162.75)	238.00(177.00,317.50)	<0.001
(pg/ml)			
Androstenedione	602.00(107.50,812.75)	1349.00(960.00,2419.50)	<0.001
(pg/ml)			
DHEA	648.00(556.50,841.00)	4054.00(2589.00,5588.50)	<0.001
(pg/ml)			
DHEA-S (*10^6)	0.14(0.08,0.25)	1.87(1.50,2.66)	<0.001
(pg/ml)			
Cortisol (*10^5)	$1.78 \pm 0.78$	$1.90\pm0.83$	0.538
(pg/ml)			
Corticosterone	3142.00(2128.25,6479.00)	3125.00(1320.00,5111.50)	0.328
(pg/ml)			
11-Deoxycortisol	811.50(664.25,1636.00)	609.00(397.00,801.00)	0.011
(pg/ml)			
11-Deoxycorticosterone	106.00(96.00,288.15)	96.000(80.00,96.00)	0.006
(pg/ml)			
Cortisone	20386.13±6388.96	21192.76±8661.66	0.716

(pg/ml)

395	Statistically significant results(P<0.05) were highlighted in bold.Comparison between groups was
396	performed using one-way ANOVA or Kruskal-Wallis test if the distribution of the respective
397	variable was not log-normal in any of the groups. DHEA, dehydroepiandrosterone; DHEAS,
398	DHEA sulfate.

399

## 400 Table 4. Accuracy of steroid biomarkers for differentiating CD form adrenal CS

	AUC (95% CI)	Sensitivity (%)	Specificity (%)	Youden index
Total	0.816	81.0%	83.3%	0.643
Testosterone(TT)	(0.682,0.951)			
> 172.5 pg/ml				
Androstenedione (A2)	0.829	100.0%	83.3%	0.875
> 917.5 pg/ml	(0.706,0.952)			
DHEA	0.972	100.0%	87.5%	0.875
>1170.5 pg/ml	(0.934,1.000)			
DHEA-S	0.958	100.0%	83.3%	0.833
> 0.27*10^6 pg/ml	(0.899,1.000)			

401 The AUCs with 95% confidence intervals of the four different androgen were included. The

402 sensitivity and specificity for each marker were derived from the optimal cutoff value. AUC: area

403 under the curve; CI: confidence interval; DHEA dehydroepiandrosterone; DHEAS DHEA sulfate.



404

Figure1. Scatter plots of reproductive hormones. Estradiol, testosterone, LH and FSH values
are displayed in (A)-(C), respectively. All comparison between the three subgroups are shown by
brackets, asterisks or text. E2, estradiol; FSH, Follicle-stimulating hormone; LH, Luteinizing
hormone; AI-CS, ACTH-independent Cushing's syndrome; CD, Cushing's disease; EAS, ectopic
ACTH syndrome. \*\*\*, P<0.001; ns, not significant.</li>



411

412 Figure2. Linear regressions between serum cortisol and reproductive hormones in 413 premenopausal and postmenopausal women. Premenopausal women with Cushing's syndrome 414 were included in (A)-(C). Postmenopausal women with CS were included in (D)-(F) to avoid 415 effects of the menstrual cycle. Pearson correlations(r) were calculated squares. FSH, 416 Follicle-stimulating hormone; LH, Luteinizing hormone.

417





Figure 3. ROC-analysis to different between adrenal CS and CD with plasma androgens.
ROC-analysis to differentiate between patients with AI-CS and CD with the most discriminative
steroids. TT, total testosterone; A2, androstenedione; DHEA, dehydrospiandrostenedione; DHEAS,

423 dehydrospiandrostenedione sulfate.



Figure4. Scatter plots of Thyroid hormone.Serum FT3,FT4 ,TSH and FT3/FT4 values are
displayed in(A)-(D).All comparison between the three subgroups are shown by brackets,asterisks
or text. TSH: thyroid-stimulating hormone; AI-CS, ACTH-independent Cushing's syndrome; CD,
Cushing's disease; EAS, ectopic ACTH syndrome. \*\*\*, P<0.001; \*\*, P<0.01; \*, P<0.05; ns, not</li>
significant.

- 431
  432
  433
  434
  435
  436
  437
  438
  439
  440
  441
  442
- 443